Search the hub
Showing results for tags 'Medication'.
-
Event
As health care systems grow increasingly complex, pharmacists are key members of the patient care team. This webinar, held by the World Patients Alliance in collaboration with the International Pharmaceutical Federation, will explore how pharmacists contribute to safer care through medication management, patient empowerment, and interprofessional collaboration. It will also highlight the patient perspective by showing how patients and families contribute to safer medication use through shared decision-making, early reporting of concerns, health literacy, and partnerships with pharmacists and other health professionals. Agenda Co-Chairs: Marianne Ivey, Professor, Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, the University of Cincinnati, USA Helen Haskell, Chair of WPA Patient Safety & Quality Council, World Patients Alliance (WPA), USA Advancing patient safety: The expanding role of pharmacists across health systems John Hertig, Adjunct Assistant Professor, Purdue University; Founder and President, Hertig Healthcare Advising LLC, USA From intervention to impact: reducing medication errors through patient-centred care Mohamed Elsabakhawi, Pharmacist/Owner, Shoppers Drug Mart, Mississauga, Canada Improving teamwork and communication for medication safety and patient-centred care Regina Mariam Namata Kamoga, Executive Director, for Community Health and Information Network (CHAIN), Uganda Panellists: John Hertig, Adjunct Assistant Professor, Purdue University; Founder and President, Hertig Healthcare Advising LLC, USA Regina Mariam Namata Kamoga, Executive Director, Community Health and Information Network (CHAIN), Uganda Mohamed Elsabakhawi, Pharmacist/Owner, Shoppers Drug Mart, Canada Register here.- Posted
-
- Pharmacy / chemist
- Pharmacist
-
(and 1 more)
Tagged with:
-
News Article
NHS patients face worst drug shortages on record, say pharmacists and GPs
Patient Safety Learning posted a news article in News
Britons are facing some of the “most severe” shortages of NHS medicines on record including common painkillers, epilepsy drugs and HRT, health leaders have warned, even forcing some patients with impaired digestive systems to skip meals. The National Pharmacy Association (NPA) has warned that medicine shortages pose a “serious risk to patient safety”. The Royal College of GPs has also raised concerns about the impact medicine shortages have on patients, GPs and pharmacists. Both have highlighted long-lasting supply issues affecting Estradot, a hormone replacement therapy (HRT) for menopausal women, and Creon, a drug taken by people with pancreatic cancer and cystic fibrosis to help them digest food. Britons are facing some of the “most severe” shortages of NHS medicines on record including common painkillers, epilepsy drugs and HRT, health leaders have warned, even forcing some patients with impaired digestive systems to skip meals. Olivier Picard, a pharmacist who chairs the NPA, said: “Medicine shortages are becoming more frequent, lasting longer and causing increasing disruption for patients.” “These shortages are some of the most severe the UK has experienced. It is deeply distressing to find patients who have travelled from pharmacy to pharmacy to find the medicines they need without success.” He said shortages were “frustrating and worrying”, and that “in some instances they pose a serious risk to patient safety”. Read full story Source: The Guardian, 18 June 2026 Further reading on the hub: Medicines shortages: minimising the impact on patients Creon shortages: “It’s just another thing patients with cystic fibrosis could do without” Medication supply issues: Mast cell activation syndrome (MCAS) Medication supply issues: A pharmacist’s perspective- Posted
-
- Medication
- Lack of resources
-
(and 1 more)
Tagged with:
-
News Article
MHRA launches AI sandbox to improve medicines safety
Patient Safety Learning posted a news article in News
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to launch a new AI regulatory sandbox aimed at improving medicines safety and accelerating the development of new treatments. The initiative, unveiled by Science Minister Lord Vallance on 9 June 2026, will provide companies and researchers with a controlled environment to test AI tools designed to predict how medicines may perform in people and identify potential safety risks earlier in the development process. Through the sandbox, the MHRA will work with industry and academic partners to assess whether AI can improve medicines safety assessment and identify risks that traditional methods may miss. Unlike the AI Airlock programme, which focuses on AI medical devices, the new sandbox will support the testing of AI tools used in medicines development and safety assessment. Up to five AI technologies will be tested during the first phase of the programme, with work due to begin in summer 2026. Lawrence Tallon, chief executive at the MHRA, said: “We’re seeing extraordinary advances in AI and biomedical science. The opportunity now is to harness them to deliver real benefits for patients. “These technologies could help us understand medicines better, generate stronger evidence on their safety, and accelerate the development of innovative treatments, especially in areas of unmet need. “For patients, that means greater confidence that the medicines they rely on are supported by the best available science, with evidence that better reflects the diverse range of people they are intended to treat.” Read full story Source: Digital Health, 16 June 2026- Posted
-
- AI
- Medication
-
(and 2 more)
Tagged with:
-
Content Article
Top picks: Key resources about diabetes
Patient-Safety-Learning posted an article in Diabetes
At Patient Safety Learning we believe that sharing insights and learning is vital to improving outcomes and reducing harm. That's why we created the hub; to provide a space for people to come together and share their experiences, resources and good practice examples. Diabetes is a condition that causes the amount of glucose in a person's blood to be too high. When you have type 1 diabetes, your body can’t make any insulin at all, whereas with type 2, you either can’t make enough insulin, or it can’t work properly. There are also other types of diabetes including gestational diabetes, which some women develop during pregnancy, maturity onset diabetes of the young (MODY) and latent autoimmune diabetes in adults (LADA). It is important that people with diabetes are supported to maintain good blood glucose control through diet, insulin and other diabetes medications, to prevent both acute and long-term complications. We’ve selected our top picks of useful resources about diabetes. Self-management is perhaps the most important aspect of treating diabetes effectively, so we've included some resources aimed at helping patients manage their diabetes too. 1 HSSIB reports The Health Services Safety Investigation Body (HSSIB) has published a series of reports considering the self-administration of insulin by people with diabetes mellitus. Each report focuses on specific groups of people who, due to their circumstances, may be at increased risk of harm because of the way they self-administer insulin. Insulin: supporting safe self-administration for patients in the community with a mental health problem Insulin: supporting safe self-administration for patients in the community with a disability Insulin: supporting patients to safe administration in inpatient settings 2 Decoding diabetes research – an innovative approach that makes scientific knowledge accessible to everyone In this blog, Jazz Sethi, Founder and Director of the Diabesties Foundation and part of the global team that developed D-Coded, discusses the need for the resource and outlines how it will help people living with diabetes to better understand and manage their condition. 3 Leading for patient safety: a conversation with Partha Kar Partha Kar, National Specialty Advisor for NHS England, has led work that has had an enormous impact for patients and for patient safety. In this video podcast, Steph O'Donohue from Patient Safety Learning talks to Partha about his leadership style and how it has helped him drive forward significant change in an often challenging context. 4 Decision support tool: making a decision about managing type 1 diabetes This leaflet from NHS England aims to help people with type 1 diabetes decide between the different technologies available to manage diabetes. It contains summaries of devices available and infographics outlining eligibility criteria for continuous glucose monitors (CGM), insulin pumps and hybrid-closed loop systems. 5 10 Year Vision: For diabetes prevention, care and treatment This report from Diabetes UK sets out a clear plan for the UK government about how it can improve health outcomes and tackle inequality for people living with diabetes by 2035. 6 D1abasics: Equipping staff to care safely for inpatients with diabetes The inpatient diabetes team at University Hospital Southampton NHS Foundation Trust recently launched D1abasics, an initiative that aims to improve inpatient care for people with diabetes. In this blog, Diabetes Consultant Mayank Patel and Inpatient Diabetes Specialist Nurse Paula Johnston outline the approach and explain how it will equip staff across all specialties with the basic knowledge to care safely for people with diabetes in hospital. 7 Improving diabetes care in inpatient mental health settings Despite the prevalence of diabetes amongst individuals with Serious Mental Illness (SMI), diabetes care is not currently audited within mental health inpatient settings as it audited in physical health settings. This project piloted an audit to assess the diabetes care within London NHS Mental Health Trusts. 8 Diabetes tech: Do national aspirations and local practice align? In this blog, a person with type 1 diabetes describes their recent experience upgrading their insulin pump, a medical device used to continuously deliver insulin instead of taking multiple daily injections. They describe how communication issues and gaps in staff knowledge led to a significant delay in accessing the pump, which caused them significant stress. They also ask whether recent announcements about increased access to diabetes technology over the next few years will match up to the reality experienced by people with diabetes accessing care at local healthcare organisations. 9 NHS England - Language Matters: language and diabetes The language that healthcare professionals use to talk about diabetes can have a profound impact on how people living with diabetes, and those who care for them, experience their condition and feel about living with it. This guidance by NHS England sets out practical examples of language that will encourage positive interactions with people living with diabetes. When people with diabetes feel encouraged and empowered to manage their condition, it has been shown to make a difference to their health outcomes. The examples in ‘Language Matters’ are based on research and supported by a simple set of principles. 10 Key things to remember if you use injectable medication to treat your diabetes This checklist by TREND Diabetes outlines the steps patients should take to ensure they inject their insulin or other diabetes medication correctly. It explains the importance of taking steps such as moving injection sites and changing needles, and outlines how failing to do this can affect blood glucose control. 11 Improving safety for diabetic inpatients: 4 key steps In this video, Partha Kar, National Specialty Advisor for Diabetes, shares four steps to improve safety for inpatients with diabetes, based on information from the National Diabetes Inpatient Audit. He also highlights key resources to help staff improve their knowledge of diabetes and understand how to offer the safest care to people with diabetes when they are staying in hospital. 12 Diabetes technology is life-changing, but we need to be prepared when it fails In this blog, Andrew Stroud talks about his family's experiences supporting their daughter, Bia, to manage her type 1 diabetes. He describes the huge value of technology in improving diabetes management and reducing the mental burden of the condition on people with diabetes and their parents and carers. However, like all technology, medical devices for diabetes can fail, and Andrew highlights the need to be prepared for this situation to ensure the person with diabetes is safe while they cannot use the devices they rely on every day. 13 How safe are closed loop artificial pancreas systems? Closed-loop artificial pancreas systems are self-regulating systems for administering insulin to patients with type 1 diabetes. They allow for tighter blood glucose control and reduce the decision-making burden for people with diabetes. In this blog, Lotty Tizzard, Patient Safety Learning's Content and Engagement Manager, takes a look at the benefits and potential patient safety risks associated with closed-loop artificial pancreas systems (APS). People with diabetes have developed the algorithm that runs these systems and made it freely available to anyone wanting to build their own DIY artificial pancreas. This has spurred the medical tech industry to develop commercial systems, which will make the technology more widely available. But there are challenges in ensuring accessibility to all people with type 1 diabetes who would benefit from the technology, and there are questions about regulation and liability. 14 A systematic approach to insulin safety (video series by Communications PharmSocNI) This video series looks at systematic approaches to insulin safety, including: Human Factors - A Journey of Discovery; SEIPS – The Swiss Army Knife Approach; and Summary & Applying the Learning. 15 System-wide strategies for better diabetes care chapter 1: Evidence approved medicines and chapter 2: Ensuring equitable access to glucose sensing technology for type 2 insulin users Two reports from Public Policy Projects (PPP). Chapter 1 calls for changes in the use of approved medicines to improve diabetes care in the UK and chapter 2 highlights the opportunities and challenges brought by CGM technology to type 2 insulin users and other patient groups. 16 National Diabetes Foot Care Audit 2018 to 2023 Ulceration of the foot in people living with diabetes presents significant challenges, including emotional, physical and financial costs, and is associated with increased risk of both amputation and death. It affects between 1 and 2% of all people with diabetes each year and its management accounts for approximately 1% of the total NHS budget. The aim of the National Diabetes Foot Care Audit is to measure factors associated with increased risk of ulcer onset and adverse ulcer outcomes, and to share information relating to best clinical practice. 17 Diabulimia: what is it and why have so few people heard of it? Type 1 diabetes with disordered eating (T1DE), or diabulimia as some experts call it, is a serious eating disorder that people with type 1 diabetes can develop where the person reduces or stops taking their insulin as a way of managing their weight. The condition can be life-threatening. Although studies are limited, it’s estimated that eating disorders affect more than a third of patients with type 1 diabetes. This episode of the Healthcare Improvement podcast looks at diabulimia and a new toolkit published by SIGN, part of Healthcare Improvement Scotland, which sets out recommendations to raise awareness and provide guidance on how best to support people living with the diabulimia. 18 NHS England: Children and young people diabetes toolkit This toolkit is designed to support integrated care systems (ICSs) to design, plan, and deliver high-quality treatment and care for children and young adults aged 0-25 years with all types of diabetes. 19 Insulin therapy in primary care The management of insulin therapy requires knowledge of the type of diabetes it is being used for and appropriate dosing, as well as correct injection technique, to prevent complications and medication errors. Diabetes nursing specialist Debbie Hicks shares key points on the management of insulin therapy for nurses in primary care. 20 Handbook: Diabetes footcare in dark skin tones Covering essential topics such as physiology, history-taking, assessment techniques, and investigative methods, this handbook has been designed to provide essential information as well as quick tips to healthcare professionals to improve foot care for people with dark skin living with diabetes. Featuring clinical assessments and visual/audio guides, this handbook is the product of a unique collaboration across healthcare professional specialities, and with input from people living with diabetes. 21 Addressing racial inequalities in paediatric diabetes Dita Aswani and Fulya Mehta are both consultant paediatricians and NHS England national advisors for Children and Young adults’ (CYA) diabetes. In this blog, they outline racial inequalities that persist in paediatric diabetes and present five key areas for change. In summary they talk about what healthcare professionals can do to reduce inequalities through their own practice. Do you have a resource or story about diabetes to share? We’d love to hear about it - leave a comment below or join the hub to share your own post.- Posted
-
- Diabetes
- Communication
- (and 6 more)
-
Content Article
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. This roundup provides a summary of their latest safety advice for medicines and medical device users. It includes details of medicine recalls, medical device field safety notices and details of how to report drug reactions and device incidents. This month's Safety Roundup includes: Drug Safety Update on Nasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overuse. Drug Safety Update on Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Device safety Information on Kimal Procedure Packs containing recalled components: Namic Angiographic Syringe with the risk of syringe disconnection; Namic Manifolds with the risk of foreign particulates. Important guidance for use in urgent procedures where there are no alternatives. Device safety Information on Risk of severe harm from use of incorrect giving (administration) set for blood transfusion. Device safety Information on Allurion Gastric Balloon: Updated safety information due to the risks of gastric outlet obstruction, small bowel obstruction and gastric perforation. Letters, medicines recalls and device notifications sent to healthcare professionals in May 2026. News and guidance on: Dostarlimab (Jemperli) and immune-related skin adverse reactions: updates to the product information. BNF and BNFC updated guidance on medicines that cause drowsiness to help prevent co-sleeping deaths.- Posted
-
- Regulatory issue
- Medication
-
(and 1 more)
Tagged with:
-
News Article
More pharmacies in England to prescribe medication from autumn
Patient Safety Learning posted a news article in News
More pharmacists in England will be able to prescribe medications as part of an effort to speed up care and ease pressure on GP surgeries and hospitals. As part of the Pharmacy First scheme, pharmacists can currently prescribe medication for a sore throat, earache, sinusitis, shingles, impetigo, infected bites and urinary tract infections. From the autumn, the new £340m investment will see five common ailments added to this list, although it is not yet clear what these will be. The Pharmacy First scheme in England was first launched in 2024, and allows patients to see their pharmacist for advice, over-the-counter treatments and prescription-only medicines. According to the Department of Health and Social Care, more than 3.3 million consultations under the scheme were carried out between March 2025 and February 2026. Health Minister Stephen Kinnock said the government is "making the most of our highly skilled pharmacists, while boosting access to services and giving patients more care right on their doorstep". "Independent prescribing will play a major part in delivering this shift, easing pressures on GPs, cutting unnecessary red tape and helping patients get the right care closer to home," he said. The NPA said that while the deal "points in the right direction", it did not address the "crippling" new costs hitting pharmacies. "We remain concerned that it does very little to close the £2.5bn funding gap that the NHS itself identified a year ago," said NPA chairman Dr Olivier Picard, adding that the expanded scheme was "nowhere near ambitious enough to transform patient access to care, nor make full use of pharmacists' skills". He went on: "We are also concerned that the current funding levels mean that many pharmacies will struggle to take this development forwards, risking its success. Pharmacies cannot sustain yet more loss-making work." Read full story Source: BBC News, 29 May 2026- Posted
-
- Pharmacist
- Pharmacy / chemist
-
(and 2 more)
Tagged with:
-
News Article
Don’t let this heatwave affect your medicines: Three important tips from the MHRA
Patient Safety Learning posted a news article in News
As the UK braces for another scorching day of high temperatures today, the Medicines and Healthcare products Regulatory Agency (MHRA) is reminding people that these hot conditions can affect medicines and how well they work. Hot weather changes how your body responds to medications, which could impact people managing long-term conditions – but a few simple steps can help avoid problems. Alison Cave, Chief Safety Officer at the MHRA, said: “Let’s face it – when there’s a heatwave, most of us are focused on getting outside and enjoying it while it lasts. But it’s easy to forget that medicines left in the heat – in cars, bags, or on sunny windowsills – might not work properly when you need them. “Some medicines can also make you more likely to burn in the sun, feel dizzy, or get dehydrated, especially if you’re taking diuretics or have a condition like asthma, heart disease, or diabetes. “To stay safe in the heat: Store medicines somewhere cool, dry and out of direct sunlight – especially if you’re out and about Know the signs of heat-related illness – stay hydrated and listen to your body Take extra care in the sun if your medicine makes your skin more likely to burn “And remember, for all medicines it’s important to read the leaflet and speak to a healthcare professional if you have any questions.” Read full press release Source: MHRA, 26 May 2026 -
News Article
NHS rollout of artificial pancreas narrows inequality in diabetes care
Patient Safety Learning posted a news article in News
The rollout of a “life-changing” artificial pancreas on the NHS for people with type 1 diabetes has helped to narrow ethnic and socioeconomic inequality within access to treatment, according to figures for England and Wales. Officially known as a hybrid closed-loop system, an artificial pancreas comprises three interconnected parts: a sensor worn on the body called a continuous glucose monitor; an algorithm either built into the pump or on a separate device such as a phone that calculates the precise dose of insulin needed; and an insulin pump that delivers the dose into the bloodstream. For patients, the device removes much of the mental burden of managing blood sugar levels, especially around mealtimes and during the night. According to previous clinical trials, the device is more effective at managing diabetes than current diabetes technology, such as using continuous glucose monitors alone. Previous rollouts of diabetes technology have had stark disparities in uptake regarding ethnicity and deprivation. Studies have shown that people from minority ethnic backgrounds in England are less likely to have access to continuous glucose monitors, while people from deprived backgrounds have been unable to have full use of this tech. However, the first two years of the artificial pancreas rollout in England and Wales has been seen to reverse this trend, with only a 3% difference in uptake between people from the most and least deprived backgrounds, as well as those from minority ethnic backgrounds compared with white counterparts. Naiha Shafiq, 27, from London, was fitted with an artificial pancreas three years ago. She said the device had been “life-changing” because she was previously in and out of hospital with diabetic ketoacidosis, a life-threatening complication, as a result of struggling to administer her insulin injections. Read full story Source: The Guardian, 19 May 2026- Posted
-
- Medication
- Diabetes
-
(and 2 more)
Tagged with:
-
News Article
The US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Louisiana sued the US Food and Drug Administration (FDA) in October in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely, arguing that it interfered with the state’s ban on abortion. The fifth circuit ruled in Louisiana’s favor on 1 May, effectively banning mail-order mifepristone for the entire country. Two mifepristone manufacturers, Danco Laboratories and GenBioPro, filed an emergency request with the supreme court, which granted a temporary stay until at least Thursday. In a 7-2 decision with dissents from justices Clarence Thomas and Samuel Alito, the court sided against the fifth circuit, ending the ban – for now. In his dissent, Thomas called the mailing of mifepristone to patients “criminal enterprise”. He also noted that the 1873 Comstock Act, which broadly banned people from using the mail to send anything “obscene, lewd or lascivious”, including “any article or thing designed or intended for the prevention of conception or procuring an abortion”, should apply to mifepristone. Medication accounts for approximately two-thirds of abortions in the US. In large part because of mailed medication, abortion rates have stayed steady in the US despite bans in several states. Years of research have shown that abortion medications are safe and effective. The recent legal challenges, after the Dobbs decision that upended nationwide access to abortion, have been based on politics rather than evidence, experts say. Read full story Source: The Guardian, 14 May 2026- Posted
-
- Pregnancy
- Medication
-
(and 2 more)
Tagged with:
-
News Article
Taking antidepressants during pregnancy does not increase the risk of children going on to develop autism or attention deficit hyperactivity disorder (ADHD), according to an analysis of more than half a million pregnancies. The study, conducted by researchers at the University of Hong Kong and published in the Lancet Psychiatry, analysed data from 37 existing studies that included 600,000 pregnant women who had taken antidepressants, and 25 million women who had no antidepressant use during their pregnancies. Before controlling for key factors such as pre-existing mental health conditions, the analysis found that antidepressant use by the mother during pregnancy was associated with a 35% increased risk of ADHD and a 69% increased risk of autism. However, when controlling for confounding factors such as pre-existing mental health conditions, this risk became non-significant. This means the meta-analysis found no significant link between antidepressant use during pregnancy and a greater risk of autism and ADHD in children, after controlling for the mother’s mental health or other influencing factors such as genetics. Dr Wing-Chung Chang, a professor at the University of Hong Kong and lead author of the study, said: “We know many parents-to-be worry about the potential impact of taking medication during pregnancy; our study provides reassuring evidence that commonly used antidepressants do not increase the risk of neurodevelopmental disorders such as autism and ADHD in children. “While all medications carry risks, so too does stopping antidepressants during pregnancy due to an increased risk of relapse. Therefore, for women with moderate-severe depression, doctors and patients must carefully weigh the potential risks and benefits of continuing antidepressant treatment during pregnancy against the potential harms of untreated depression. “Although our study found a small increase in the risk of autism and ADHD in the children of women who had used antidepressants during pregnancy, it also found that this risk disappeared when we accounted for other factors. The increased risk was also seen in the children of fathers who took antidepressants and of mothers with antidepressant use before, but not during, pregnancy. “Together, this suggests that it is not the antidepressants themselves causing an increased risk in autism and ADHD but it is more likely to be due to other factors, including genetic predisposition to conditions such as ADHD, autism, and mental health conditions.” Read full story Source: The Guardian, 14 May 2026- Posted
-
- Medication
- Research
-
(and 4 more)
Tagged with:
-
Content Article
At Patient Safety Learning we believe that sharing insights and learning is vital to improving outcomes and reducing harm. That's why we created the hub; providing a space for people to come together and share their experiences, resources and good practice examples. Dementia is an umbrella term for a number of diseases that affect the brain, with Alzheimer’s disease its most common cause. We have picked a range of resources and reflections about keeping people with dementia safe in health and care settings, and when considering medication choices. 1 Alzheimer's Society: Checklist for possible dementia symptoms This checklist has been developed by the Alzheimer’s Society to allow patients to check symptoms that could be a possible sign of dementia. Endorsed by the Royal College of General Practitioners (RCGP), it is a simple tool to help patients and their families clearly communicate their symptoms and concerns to a GP or other healthcare professional. 2 Seeing the unseen: Rethinking dementia diagnosis Across 2024 and 2025, Alzheimer’s Research UK surveyed more than 500 people affected by dementia and over 160 healthcare professionals to understand the realities of diagnosis. This report shares findings from this process and considers what works, what gets in the way, and what needs to change. 3 Health and social care support for people with dementia The Care Quality Commission (CQC) looked at people's experiences of living with dementia when using health and adult social care services, including the experiences of families and carers. It sets out the main themes that influence whether an experience is good or poor, and what health and care services are doing to improve these experiences. CQC will use the findings in this report to help shape their work to define what good care looks like for people with dementia and inform the next phase of CQC’s Dementia Strategy. 4 Keeping patients with dementia safe: an interview with Alison Keizer and Fran Hamilton When people with dementia enter a new healthcare setting, the environment may be confusing and difficult to navigate. They may be unable to use their usual coping strategies and have difficulty communicating their needs and concerns to staff. This can present a wide range of risks to their safety while accessing care. In this interview, Alison Keizer, trust-wide Dementia Lead, and Fran Hamilton, Occupational Therapist and Deputy Dementia Lead at Sussex Community NHS Foundation Trust, describe the patient safety issues affecting patients with dementia and suggest how they can be supported to reduce these risks. 5 World Alzheimer Report 2025: Reimagining life with dementia – the power of rehabilitation This report from Alzheimer's Disease International explores the important topic of dementia rehabilitation, combining expert essays and real-world case studies from multiple countries globally to examine how the concept is defined and implemented, as well as practical considerations of how to best adapt rehabilitation practices for people living with dementia in different contexts. 6 National Audit of Dementia: Spotlight Audit in Memory Assessment Services 2023/24 This report examines waiting times, access to assessments, treatment, and post-diagnostic support for people with dementia in memory assessment services. The results indicate that there is still a great deal of variation between services in key results such as average waiting time for patients, the proportion of patients diagnosed with dementia, and the provision of post diagnostic support and therapy. 7 The role of integrated care systems in improving dementia diagnosis The Alzheimer’s Society commissioned The King’s Fund to explore the development of Integrated Care Systems (ICSs) through the lens of dementia diagnosis—to consider what opportunities ICSs present to approach dementia differently and to improve diagnosis rates by doing so. The research team explored enablers and barriers to improving dementia diagnosis through interviews with stakeholders and people affected by dementia in three case study ICSs. 8 Alzheimer's Society: 'This is me' leaflet This simple leaflet was developed by the Alzheimer's Society for anyone living with dementia, or experiencing delirium or other communication difficulties. It provides a central place where those closest to the person can fill in key information about them, such as their preferred name, cultural background, routines and likes and dislikes. The leaflet can then be shown to health and social care professionals in new and unknown settings to help them better understand the person and deliver care that is tailored to their individual needs. 9 Dementia UK: Making the home safe and comfortable for a person with dementia Dementia can have a significant impact on a person’s daily life, including how well they function within their home. Memory issues or problems recognising and interpreting the objects around them can cause the person frustration or create safety issues. Dementia UK have produced a leaflet with tips and guidance on how to make the home more safe for someone with dementia. 10 Alzheimer's Society: Tips for carers - questions to ask the doctor about antipsychotics Antipsychotic drugs may be prescribed for people with dementia who develop symptoms such as aggression and psychosis. This webpage from the Alzheimer's Society provides information on the prescription of antipsychotic medications for people living with dementia. It describes their potential side effects and includes a list of helpful questions that carers should ask healthcare professionals before the person they care for is prescribed antipsychotic medication. 11 Assessment, diagnosis, care and support for people with dementia and their carers: A national clinical guideline These national clinical guidelines from Health Improvement Scotland, the first to be published in nearly 20 years, provide recommendations on the assessment, treatment and support of adults living with dementia. It calls for greater awareness of pre-death grief for people with dementia, their carers and their loved ones, as they fear the loss of the person they know. To accompany the guidelines, a podcast has been produced by Health Improvement Scotland speaking to professionals, including Dr Adam Daly, Chair of Healthcare Improvement Scotland’s Guideline Development Group and a Consultant in old age psychiatry, and Jacqueline Thompson, a nurse consultant and the lead on pre-grief death for the guideline. 12 Alzheimer’s Society: Improving access to a timely and accurate diagnosis of dementia in England, Wales and Northern Ireland A formal diagnosis of dementia can help people living with the condition and their families gain a better understanding of what to expect and help to inform important decisions about treatment, support and care. This report from the Alzheimer's Society highlights the barriers to accessing a timely and accurate dementia diagnosis and advocate for practical changes and tangible solutions to overcome them. 13 The current state of dementia diagnosis and care in England The current dementia care system remains fragmented, underfunded, and difficult to navigate, leaving many individuals and families unsupported. In response to these systemic challenges, Care England, in partnership with Dementia Forward and care providers, conducted a national survey in January 2025. This initiative aimed to capture the experiences of people living with dementia, their families, and care staff. The findings highlight significant gaps and inequalities in the dementia care pathway and inform a set of urgent policy recommendations. 14 Raising awareness of normal pressure hydrocephalus: an often misdiagnosed condition Normal pressure hydrocephalus (NPH) is a progressive neurological condition that comes under the dementia umbrella. In NPH, the cerebrospinal fluid-filled ventricles within the brain expand and distort the surrounding tissues. This process causes the neurological symptoms of NPH. Unlike other forms of hydrocephalus, NPH does not result in significantly raised intracranial pressure. NPH is often misdiagnosed as it is similar to neurodegenerative conditions such as Parkinson’s disease and other causes of dementia, such as Alzheimer's disease. However, unlike these other conditions, if diagnosed early there is an effective treatment that can significantly slow disease progression and potentially improve, or even reverse, symptoms in some people. 15 The training gap: a hidden injustice in dementia care and how to fix it This report from Alzheimer's UK reveals huge gaps in dementia training across social care: half of staff receive just one to two hours of dementia learning despite 70% of care home residents living with the condition. It argues that these shortfalls in training are leaving social care staff unprepared, unsupported, and putting people with dementia at risk of inadequate care. It calls on the government to build a bold and ambitious dementia plan, which includes mandatory dementia training for care staff. 16 Alzheimer's Society: Unlocking the door to dementia diagnosis and treatments Systems designed to diagnose and support people with dementia are struggling to keep pace, with delays, inequalities and missed opportunities far too common. Too many people have a poor experience, wait too long for a diagnosis and receive less treatment and support than clinical guidance says they should. Everyone with dementia has the right to an early and accurate diagnosis and the best available treatments. Alzheimer's Society’s two 'Unlocking the door' reports lay out a stark reality – and a clear programme of reform for England, Wales and Northern Ireland. For more resources, take a look at our Dementia area of the hub. Do you have a resource or story to share about dementia or a related condition? Could your insights or experiences help improve patient safety? Leave a comment below (join the hub for free first) or contact us at [email protected].- Posted
-
- Dementia
- Medication
- (and 5 more)
-
News Article
NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease
Patient Safety Learning posted a news article in News
Hundreds of children with a rare muscle-wasting disease will be able to receive two drugs that can improve their survival in a move parents hailed as a “lifeline”. The National Institute for Health and Care Excellence (Nice) has published final draft guidance recommending that any patient who would benefit can have either drug. The move means that anyone in England, Wales or Northern Ireland with spinal muscular atrophy will from Thursday be able to get either nusinersen, also known as Spinraza, or risdiplam, also known as Evrysdi, from the NHS. SMA is a progressive genetic disorder that causes severe muscle weakness and can affect the ability to move, breathe and swallow. Without treatment, patients face devastating consequences including profound disability and reduced life expectancy. Children with the most severe form of SMA – type 1 – usually die before they reach two. Prof James Palmer, NHS England’s national medical director for specialised services, said: “These lifeline treatments have offered a phenomenal step forward in care for children and families affected by such a debilitating condition and it is fantastic that they will now be available on the NHS in the long term. “For parents who faced the unimaginable pain of thinking their child would not reach their second birthday, they now have hope of seeing them walk to school and play with their friends, thanks to these lifechanging new therapies.” Read full story Source: The Guardian, 14 May 2026- Posted
-
- Children and Young People
- Medication
-
(and 1 more)
Tagged with:
-
News Article
Updated safety advice has been issued to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on dutasteride. Following an additional detailed review of the evidence, including the outcome of a European regulatory review, the MHRA has published a new Drug Safety Update and is updating product information for medicines containing finasteride and dutasteride to provide clearer guidance for healthcare professionals and patients. Finasteride is used to treat male pattern hair loss at a dose of 1mg, and benign prostatic hyperplasia at a dose of 5mg. Dutasteride (0.5mg) is used to treat benign prostatic hyperplasia. The updates include: strengthened warnings in the product information for finasteride 1mg for androgenetic alopecia to clarify that sexual dysfunction may contribute to mood disorders, and that sexual dysfunction has also been reported with and without mood alterations. a precautionary warning added to the product information for dutasteride to note that mood alterations have been reported with a medicine in the same class, finasteride. Existing UK patient alert cards for finasteride, introduced in 2024, remain in place. These cards highlight the risks of sexual dysfunction, depression and suicidal thoughts and advise patients on what action to take if side effects occur. Read full story Source: MHRA, 11 May 2026- Posted
-
- Medication
- Adverse reaction
-
(and 1 more)
Tagged with:
-
Content Article
This Patient Safety Supplement, issued by the Health Service Executive in the Republic of Ireland, aims to raise awareness among patients and healthcare staff of the risk of paracetamol-induced hepatotoxicity (harm to the liver) from standard doses of paracetamol in some adult patients. Paracetamol-induced hepatotoxicity may result in acute liver failure, the need for liver transplantation and/or death. Symptoms can include stomach pain, nausea (feeling sick) or vomiting, jaundice (skin or eyes look yellow), confusion, drowsiness or sleepiness and not urinating as much as normal. -
News Article
‘Breakthrough’ drug for severe muscle wasting condition set for NHS rollout in England
Mark Hughes posted a news article in News
Hundreds of children across England are set to benefit from a new drug which has been approved for rollout on the NHS to treat a severe muscle-wasting condition. Givinostat is expected to enable eligible patients with Duchenne muscular dystrophy to maintain their mobility for longer. The National Institute for Health and Care Excellence confirmed the drug's availability after its manufacturer reached a commercial agreement with NHS England. This decision marks a significant step for families affected by the rare genetic disorder. While campaigners welcomed the long-awaited approval, they highlighted the "agonising" two-year process, during which many families were left without access to the drug as their child's condition continued to deteriorate. Read more here. Source: The Independent, 8 May 2026 -
News Article
Epilepsy patients are living with the risk of having “life-threatening” seizures as drug supply problems are forcing some to skip their medication. There are hundreds of drugs, including those for epilepsy, blood pressure, blood thinning and some cancer medicines, that patients are finding harder to get hold of in England. For the 630,000 people with epilepsy living in the UK, these medicines help them safely live their lives and skipping a dose can have potentially deadly consequences. “It’s really scary to think that through no fault of my own, this could be the reason I don’t wake up in the morning,” Beth Baker-Carey told the Independent. The 28-year-old from Doncaster, who has suffered from seizures since she was two, once had ten seizures a day, but medication keeps her stable. Although medicine shortages are common, she explained it has worsened since the start of the war in Iran. The department of health and social care is aware of supply issues with some epilepsy medications, but has said these are not directly linked to the war. Ms Baker-Carey has been notified several times by pharmacies that they have no stock in recent months. “I’ve had to jump through hoops and go to different pharmacies to get medication,” she said. “A couple of times it has been quite late at night and I’ve not been able to get it. I’ve been told to just skip it for the night, which is not really wise for a person with epilepsy, skipping can be really dangerous and sometimes fatal." Read full story Source: The Independent, 6 May 2026 Further reading on the hub: Creon shortages: “It’s just another thing patients with cystic fibrosis could do without” Medication supply issues: Mast cell activation syndrome (MCAS)- Posted
-
- Epilepsy
- Medication
- (and 3 more)
-
News Article
US appeals court blocks mail-order access to abortion drugs
Patient Safety Learning posted a news article in News
Access to mifepristone, the FDA-approved medication used to end pregnancy, could become severely limited following a ruling from a US appeals court on Friday, which temporarily blocked the drug from being dispensed through the mail. The decision is for now the most sweeping threat to abortion access since the supreme court rolled back abortion rights in 2022, said Kelly Baden, vice-president at the Guttmacher Institute, an abortion rights advocacy group. “If allowed to stand, it would severely restrict access to mifepristone in every state, including those where abortion is broadly legal and where voters have acted to protect abortion rights,” she said. The so-called “abortion pill” is part of a two-drug regimen backed by decades of evidence for its efficacy and safety, and is used in the majority of abortions in the US. Usage has risen in recent years, especially in the aftermath of the 2022 ruling from the supreme court that overturned federal protections for the right to an abortion. In the year after that decision, the FDA formally modified its regulations to allow the drug to be prescribed online, expanding its use even in states where abortion care was being constricted. The drug has become a key target for the anti-abortion movement, and a series of lawsuits have challenged the drug’s initial approval in 2000 and the subsequent rules making it easier to obtain. Meanwhile, with the FDA now under Trump, the agency has opened a review of the medication. Once this analysis is completed, officials at the agency said, they will determine if changes to its regulations are warranted. Reproductive rights advocates have voiced concerns that the review could further limit mifepristone’s use, despite the evidence supporting its safety. Read full story Source: The Guardian, 4 May 2026 -
Content Article
Mental Health Awareness Week is an annual event which aims to raise awareness and promote open conversations about mental health. In this Top picks, we’ve pulled together resources, blogs and reports from the hub that focus on improving patient safety across different aspects of mental health services and also supporting staff with their own mental health and wellbeing. 1 World mental health today: latest data (WHO, 2025) This World Health Organization (WHO) document draws on the latest information available to outline the state of mental health and mental health systems in the world. It shows that mental health conditions remain highly prevalent, with more than a billion people worldwide living with a mental disorder. This report provides essential data to guide national and global dialogue. It highlights where progress is being made – and where critical gaps persist. This report should serve as a vital tool for policy-makers, implementers and advocates alike. 2 Jay’s Personalised Safety Planning Toolkit: A guide to support meaningful safety planning for self-harm and suicide This toolkit is a co‑designed set of materials created with researchers, people with personal experience of suicide and self-harm, and healthcare professionals. Inspired by the family of Jaymie Mart, known as Jay, who died by suicide in 2012 at the age of 32, the toolkit—which was funded by the National Institute for Health and Care Research (NIHR)—offers clear, practical guidance to help adults create and review personalised safety plans. 3 Harry’s story: Acute Behavioural Disturbance In December 2022, Harry Vass died after experiencing Acute Behavioural Disturbance (ABD) and a complex disturbance in normal physiology. Harry’s death was found to be avoidable as carers were not fully aware of this condition associated with acute psychosis. In this blog, Harry’s mother Julie describes the barriers they faced in getting the right support and care for Harry before he died and highlights the need for healthcare staff to have a greater awareness of ABD and the associated risks of a medical emergency. You can also read a second blog by Julie, where she explains more about Acute Behavioural Disturbance and the changes she believes are needed to make sure patients like Harry are cared for appropriately. 4 Life Beyond the Cubicle: eLearning to support working well with families during mental health crises A set of eLearning modules designed to educate and update clinicians on the importance of involving families wherever possible during mental health crises to improve patient care, avoid harm and reduce deaths. They were developed as a partnership between Oxford Health NHS Foundation Trust and Making Families Count, with funding from NHS England South East Region (HEE legacy funds). The resources have been co-produced by people with lived experience as patients, family carers and clinicians, supported by an Advisory Group drawn from a wide range of expertise, tested in eleven NHS Trusts and independently evaluated. 5 Mental health crises: how to improve care In May 2024, National Institute for Health and Care Research (NIHR) Evidence held a webinar on care for adults in mental health crisis. The webinar shared research findings on what works in community crisis care, how acute day units compare to crisis resolution teams and whether peer-supported self-management can reduce acute readmissions. This Collection summarises the 3 research projects presented at the webinar. It includes video clips from the speakers and incorporates quotes from the day. The information will be useful for anyone involved in commissioning or delivering mental health crisis services. 6 Self-harm: assessment, management and preventing recurrence This new guideline from the National Institute for Health and Care Excellence (NICE) covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed. The guideline sets out some important principles for care and treatment. For example, it states that self-harming patients treated in primary care must receive regular follow-up appointments, regular reviews of self-harm behaviour and a regular medicines review. 7 Hope Virgo: What needs to happen to stop people with eating disorders being failed by the healthcare system? In this blog, Hope Virgo, author and Secretariat for the All Party Parliamentary Group (APPG) on Eating Disorders, examines the crisis that continues in eating disorder services in the UK and the devastating impact this is having on patients and their families. She highlights how failures in services lead to avoidable deaths. Hope shares the key recommendations from a new report by the APPG and calls for adequate funding and attention to ensure people with eating disorders receive the help they need to recover. 8 Designing paediatric wards to support mental health Blog from the Health Services Safety Investigations Board (HSSIB) authored by Saskia Fursland, Senior Safety Investigator. She talks about her visit to a newly opened paediatric ward where its design has carefully considered children and young people with mental health needs. Saskia reflects on the learning which could support other paediatric wards to improve their environments. 9 Zero Suicide Alliance training The Zero Suicide Alliance is a collaboration of NHS trusts, charities, businesses and individuals who are committed to suicide prevention in the UK and beyond. Their website offers free online training courses to teach people the skills and confidence to have potentially life-saving conversations with someone they’re worried about. They offer short online modules covering general suicide awareness, social isolation and suicide in veterans and university students. 10 How can our team move past a traumatic event? After an extreme traumatic event there are things that you can do to help yourself, and your colleagues, to move on. Fiona Day, medical and public health leadership coach and chartered coaching psychologist, Stacey Killick, consultant paediatrician at Glan Clwyd Hospital, and Lucy Easthope, professor in practice at Durham University’s Institute of Hazard, Risk, and Resilience and adviser on disaster recovery give their tips in this BMJ article. 11 Trusted information collection: severe mental illness (Patient Information Forum) The Patient Information Forum (PIF) have launched a series of new collections to help people find trusted resources. Each collection only features resources that have the PIF TICK. That means they are easy-to-read, evidence-based and easy to understand. Topics include: schizophrenia, bipolar disorder and psychosis. 12 Vicarious trauma: The invisible epidemic In healthcare, an insidious epidemic lurks beneath the surface, affecting the very individuals tasked with providing care: vicarious trauma by empathy. Despite its profound impact, this phenomenon remains largely unrecognised and under-discussed within the sector. As leaders, it is imperative that we shed light on this invisible trauma and acknowledge it as one of the greatest challenges facing our industry, as Margarida Pacheco explains in this blog. 13 Beyond stereotypes: A lived experience guide to navigating support for disordered eating Disordered eating can affect anyone, but it can be confusing to understand and recognise it in our own personal experiences. This guide, published by East London NHS Foundation Trust, is a snapshot of how adults in East London have navigated those experiences of uncertainty while seeking support for disordered eating. For many of the contributors, preconceptions about what an eating disorder is (or isn’t) have previously acted as a barrier to seeking or receiving support. It also contains advice on how to seek support for disordered eating. 14 “The alarming rate of suicide among healthcare workers should be a wake-up call in the urgent need to support them” Frontline19 was established at the start of the Covid pandemic as an urgent response to support frontline workers who were under extreme pressure and experiencing significant mental health challenges. Psychotherapist Claire Goodwin-Fee is the founder and CEO of Frontline19. In this blog, Claire explains how systemic pressures and stigma around mental health are continuing to leave healthcare staff extremely vulnerable. 15 Blog: Why harmful gender stereotypes surrounding men’s approaches towards their feelings need challenging This blog explores why men are reluctant to seek support when they are struggling with their mental health and why the suicide rate is so high. It looks at initiatives that exist to encourage men to seek help and highlights what more could be done to support mens’ mental health. 16 Time for a rebalance: psychological and emotional well-being in the healthcare workforce as the foundation for patient safety In this editorial for BMJ Quality and Safety, Kate Kirk explains why staff well-being is the foundation to improving patient safety. 17 Top tips and key actions for successful collaborative partnership working across mental health services These top tips and key actions have been co-developed to support effective collaborative partnership working in the planning and delivery of community mental health services. They recognise that every heath and care system will experience challenges in relation to partnership working given the statutory and cultural differences of organisations working across the mental health pathways and that there will be different arrangements to frame local partnership working, including for example a Section 75 agreement. 18 Balancing care: The psychological impact of ensuring patient safety In this blog, Leah Bowden, a patient safety specialist, reflects on the impact her job has on her mental health and family life. She discusses why there needs to be specialised clinical supervision for staff involved in reviewing patient safety incidents and how organisations need to come together to identify ways we can support our patient safety teams. 19 NHS England: Staying safe from suicide: Best practice guidance for safety assessment, formulation and management This guidance supports the government’s work to reduce suicide and improve mental health services. It promotes a shift towards a more holistic, person-centred approach rather than relying on risk prediction, which is unreliable because suicidal thoughts can change quickly. Instead, it recommends using a method based on understanding each person’s situation and managing their safety. 20 The Motherhood Group: Black maternal mental health report UK The Motherhood Group has launched a landmark report on Black maternal mental health in the United Kingdom, shining a light on the urgent need for safe spaces, culturally competent peer support, digital access, and community-driven, anti-racist solutions. This report centres the lived experiences of Black mothers and highlights systemic barriers to quality, affordable mental healthcare. By leading this research, The Motherhood Group places Black mothers’ voices at the forefront of national conversations, providing policy-makers, health services, and communities with the insights needed to drive meaningful change. 21 Mental Maintenance at NEAS: a proactive approach to staff mental health The North East Ambulance Service NHS Foundation Trust (NEAS) provides emergency medical and patient transport services to a population of 2.7 million people in the North East region, employing over 3,400 staff members. Exposure to traumatic events, the demands of shift working and an uncertainty of what’s in store each day, can impact ambulance staff mental health. Read how North East Ambulance Service NHS Foundation Trust created a campaign to provide proactive staff mental health support. 22 Mind: The big mental health report 2025 Mind’s 2025 Big Mental Health Report explores the state of mental health, and mental health services and support across England and Wales. It builds on the insights from their 2024 report and gives a comprehensive picture of mental health to date, serving as a crucial guide that anyone can use. It explores the latest evidence on the nation’s mental health including how well services are supporting mental health in England and Wales. 23 Making sense after a suicide: living with blame, uncertainty, and the need for answers. You are not alone Each year, more than 700,000 people die by suicide worldwide. In the UK, it is around 7,000 – making it the biggest cause of death for people aged 20–34 and for men under 50. Making Families Count have created this resource to offer some comfort, recognition, and companionship in the aftermath of bereavement by suicide, whether it seems the person intended to take their own life, or their intention was unclear. The resource consists of a booklet and three short films of people’s stories of their bereavement by suicide. Written by Dr Rachel Gibbons, with contributions from a group of bereaved families, Dr Karen Lascelles, and comments and suggestions from other affected people and those who work with them. 24 National Audit of Eating Disorders Service Mapping Report 2025 The National Audit of Eating Disorders (NAED) is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England as part of the National Clinical Audit and Patient Outcomes Programme. In 2025 the NAED team conducted a comprehensive mapping of eating disorder service provision across England. This report provides an in-depth overview of NHS-funded and independent sector services for children, young people, and adults. 25 Mental health crisis care: legislative challenges in emergency departments (HSSIB) The Health Services Safety Investigations Body (HSSIB) published two reports intended for healthcare organisations, policymakers and the public to help improve patient safety in relation to safety issues identified for people experiencing a mental health crisis who come into contact with urgent and emergency care services. This first report focuses on the significant legal, policy and safety gap in the care of people in emergency departments (EDs) in mental health crisis. During consultation on this report, concerns were shared with HSSIB about the current challenges in relation to the resourcing and configuration of mental health services that exacerbate challenges faced in the ED. 26 Mental health: attempted suicide while under the care of community services (HSSIB) The second HSSIB investigation used the patient safety incident investigation (PSII) report template and Patient Safety Incident Review Framework (PSIRF) tools to investigate an attempted suicide in the community mental health setting. Findings and areas for improvement are listed for the organisations that were involved in this incident. However, the learning may be relevant to other organisations. Have your say Do you have any stories, insights or resources related to mental health? We would love to hear from you! Comment below (register for free here first) Get in touch with us directly to share your insights.- Posted
-
1
-
- Mental health
- Health inequalities
- (and 8 more)
-
News Article
Watchdog uncovers £1.8m illegal medicines and steroids network
Patient Safety Learning posted a news article in News
A large-scale criminal network supplying illegal steroids and prescription-only medication worth £1.8 million has been uncovered by the medicines watchdog, leading to seven men being sentenced. The investigation by the Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit discovered more than 130,000 doses of steroids and unauthorised medicines, including products such as tamoxifen, finasteride and modafinil. The illegal supply was traced after a website linked to the Bolton area was suspected of selling performance-enhancing steroids and other illegal medicines by the UK Anti-Doping (UKAD). MHRA investigators traced the activity to a flat above commercial premises on St Helens Road in Bolton, which was being used to store, package, and distribute the drugs. Seven men were charged with offences including conspiracy to supply controlled drugs, supplying unauthorised medicines, and money laundering to the value of over £1.8 million and received combined sentences totalling more than 21 years’ imprisonment. “This was a well-organised operation that put people at real risk. Medicines bought outside regulated channels can be unsafe, ineffective or fake,” Tim Duffield, MHRA Head of Intelligence said. Read full story Source: The Independent, 30 April 2026- Posted
-
- Criminal behaviour
- Medication
-
(and 1 more)
Tagged with:
-
News Article
The struggle to get hold of medication in England is set to get worse
Patient Safety Learning posted a news article in News
"It's just terrifying," Chloe says. "I get panic attacks." The 29-year-old has epilepsy and is struggling to get the drugs she needs to prevent life-threatening seizures. Her Lamotrigine-based medication is one of hundreds of everyday drugs that are now extremely hard to get hold of in England. She has other medications that she can easily get, but the one that helps her to safely live her life and go to work is the one that she struggles to get access to. "In the last few weeks I haven't been able to get the right medications and my seizures came back. I fell and hit my head and have a big scar across my back now from it," Chloe says. Access to medicines in England is at its most fragile point in years. People living with heart conditions, stroke risks, eye infections, bipolar and ADHD - to name just a few - are among those unable to get the medications they depend on. Shortages are caused in part by surging global prices. However, the problem is also being exacerbated by a complicated process of funding medicines in the UK. For patients, it often means rounds of phone calls and anxiety. Chloe says she sometimes sits on the bus for several hours "going on patrol" hunting for the medication she needs. Read full story Source: BBC News, 1 May 2026 Related reading on the hub: Creon shortages: “It’s just another thing patients with cystic fibrosis could do without” Medication supply issues: Mast cell activation syndrome (MCAS) Medication supply issues: A pharmacist’s perspective Medicines shortages: minimising the impact on patients (a blog by Catherine Picton)- Posted
-
- Medication
- Lack of resources
-
(and 2 more)
Tagged with:
-
Content Article
Summary of the latest safety advice for medicines and medical device users from the Medicines and Healthcare Regulatory products Agency (MHRA). This month's Safety Roundup includes: Letters, medicines recalls and device notifications sent to healthcare professionals in April 2026. News and guidance on: EMA recommends withdrawal of marketing authorisations for levamisole medicines following safety review. Publication of RSV vaccine factsheet. -
News Article
Precautionary recall of antidepressant medication due to manufacturing error
Patient Safety Learning posted a news article in News
The Medicines and Health products Regulatory Agency (MHRA) has advised healthcare professionals to stop supplying the affected batch of Sertraline 100mg and return all remaining stock to their suppliers. Amarox Limited is recalling one batch of Sertraline 100mg film-coated tablets as a precautionary measure due to a manufacturing error that led to two antidepressant medicines being packaged incorrectly. The recall follows a patient complaint which helped identify that a pack of Sertraline 100mg film-coated tablets contained one blister strip of Citalopram 40mg film-coated tablets inside the sealed carton. Sertraline and citalopram are both selective serotonin reuptake inhibitors (SSRIs) used to treat depression, anxiety disorders, and related mental health conditions by boosting brain serotonin. Both SSRI medications are produced by the same manufacturer, at the same site, and the error appears to have occurred during secondary packaging of the blister strips into the cartons. Patients who believe they have already taken any Citalopram 40mg tablets by mistake or are experiencing side effects, are advised to seek medical advice immediately. Read full press release Source: MHRA, 28 April 2026- Posted
-
- Medication
- Packaging/ labelling/ signage
-
(and 1 more)
Tagged with:
-
News Article
One of the biggest producers of hormone replacement therapy has been censured by regulators for “systemic failures” that jeopardised patient safety. Theramex, the UK producer of HRT drugs Evorel and Intrarosa, was found to have breached fundamental compliance standards including not updating crucial prescribing information – in some cases for several years – and not making it clear that a drug must not be used during pregnancy. The Prescription Medicines Code of Practice Authority (PMCPA), the UK drug industry’s self-regulatory body, issued the public reprimand against Theramex after its own staff blew the whistle over “alarming” compliance issues and incomplete prescribing information for Evorel and Intrarosa that “jeopardise patient safety”. Evorel patches – which contain estradiol – are among the most prescribed form of transdermal HRT, with more than 250,000 items issued in the last financial year, according to NHS Business Services Authority figures. Overall, nearly 10m items of estradiol, including gels, were prescribed in the 2024/25 financial year. The employees’ concerns included failing to provide comprehensive side-effect information in Evorel’s prescribing information, and not updating Intrarosa’s product information since 2019. The PMCPA also reprimanded the company for failures to specify in its advertising at a reproduction and advertising conference that Yselty (linzagolix), used to treat uterine fibroids, should not be taken during pregnancy. In all, PMCPA found that Theramex breached the Association of the British Pharmaceutical Industry (ABPI)’s code of practice 21 times. The panel said these breaches not only jeopardised patient safety, but that Theramex has “brought discredit upon, and reduced confidence in, the pharmaceutical industry”. Read full story Source: The Guardian, 22 April 2026- Posted
-
- Womens health
- Menopause
- (and 4 more)
-
News Article
Precautionary recall of blood pressure medication after manufacturing error
Patient Safety Learning posted a news article in News
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers. Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure due to a potential manufacturing error which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg. This follows a complaint from a patient where it was identified that, inside a sealed carton of Ramipril 10mg capsules, one blister pack of Ramipril 5mg capsules was found. Both product batches were manufactured at the same manufacturing site, and the error appears to have occurred during secondary packaging of the cartons. The risk to patients of taking the lower dose of this medicine for a limited time is very low. Dr Alison Cave, MHRA Chief Safety Officer, said: “If you take Ramipril 10mg, check the packaging for batch number GR174091. The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication name on the carton matches the blister strips inside. “If the 10 mg carton of Ramipril contains blister strips that are labelled as Ramipril 5mg capsules, contact your dispensing pharmacy. If the carton contains blister strips that are correctly labelled as Ramipril 10mg capsules, you do not need to take further action.” If you have an impacted pack or previously received this batch and you believe you have taken any Ramipril 5mg capsules that were included in error and are currently experiencing any adverse effects, please seek medical advice. Please take the leaflet that came with your medicine and any remaining tablets with you to your pharmacy or GP practice. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme. If you’ve already taken Ramipril 5mg, please be reassured that there is a very low risk to your health. Both strengths of the medication are used to treat high blood pressure, heart failure, and kidney disease. Any possible impact of a lower dose of Ramipril is expected to be gradual rather than immediate or life threatening. The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers. Press release Source: MHRA, 20 April 2026 -
News Article
Steroids and the ‘silent’ cancer plaguing the manosphere
Patient Safety Learning posted a news article in News
The patient, to look at him, was in the prime of his life: in his late thirties, fit and toned from hours spent in the gym. But the scans told a different story. Growing on his liver was a malignant tumour the size of a bowling ball. The obsession that had given him his chiselled physique had handed him a death sentence. The patient — like thousands of other gymgoers in the UK — had been taking anabolic steroids. The cancer was inoperable. There was nothing his doctors could do for him. “His life expectancy is probably about six or seven months,” said Stephen Wigmore, regius professor of clinical surgery at the University of Edinburgh. This was not the first young man whom Wigmore, who is also the head of surgery at the Royal Infirmary of Edinburgh, had treated for liver cancer after heavy steroid use. He said the illegal trade in steroids in gyms, taken by predominantly young men pursuing the ideal of a masculine body, had created a “silent killer”. And he said this was encouraged by social media and the “manosphere” — a loose collection of online influencers and chat forums pushing misogynistic views and a new idea of masculinity. It is hard to tell the scale of the threat. “We are not talking about an epidemic,” Wigmore said. “This is very rare, but I’ve seen two cases in the last six months. And across the country each liver unit is seeing small numbers of young men in similar situations. “The irony of taking drugs to make oneself more beautiful but ultimately shortening one’s life is inescapable,” he said, comparing the phenomenon to the obsession of some young women with risky cosmetic surgery such as Brazilian butt lifts. Read full story (paywalled) Source: The Times, 18 April 2026- Posted
-
- Medication
- Mens health
-
(and 2 more)
Tagged with: